IBDEI0L5 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10366,0)
 ;;=V16.41^^67^675^9
 ;;^UTILITY(U,$J,358.3,10366,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10366,1,4,0)
 ;;=4^V16.41
 ;;^UTILITY(U,$J,358.3,10366,1,5,0)
 ;;=5^Family h/o Cancer of Ovary
 ;;^UTILITY(U,$J,358.3,10366,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,10367,0)
 ;;=V16.42^^67^675^10
 ;;^UTILITY(U,$J,358.3,10367,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10367,1,4,0)
 ;;=4^V16.42
 ;;^UTILITY(U,$J,358.3,10367,1,5,0)
 ;;=5^Family h/o Cancer of Prostate
 ;;^UTILITY(U,$J,358.3,10367,2)
 ;;=^317952
 ;;^UTILITY(U,$J,358.3,10368,0)
 ;;=V16.43^^67^675^11
 ;;^UTILITY(U,$J,358.3,10368,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10368,1,4,0)
 ;;=4^V16.43
 ;;^UTILITY(U,$J,358.3,10368,1,5,0)
 ;;=5^Family h/o Cancer of Testis
 ;;^UTILITY(U,$J,358.3,10368,2)
 ;;=^317953
 ;;^UTILITY(U,$J,358.3,10369,0)
 ;;=V19.5^^67^675^13
 ;;^UTILITY(U,$J,358.3,10369,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10369,1,4,0)
 ;;=4^V19.5
 ;;^UTILITY(U,$J,358.3,10369,1,5,0)
 ;;=5^Family h/o Congenital Anomalies
 ;;^UTILITY(U,$J,358.3,10369,2)
 ;;=^295325
 ;;^UTILITY(U,$J,358.3,10370,0)
 ;;=V19.2^^67^675^14
 ;;^UTILITY(U,$J,358.3,10370,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10370,1,4,0)
 ;;=4^V19.2
 ;;^UTILITY(U,$J,358.3,10370,1,5,0)
 ;;=5^Family h/o Deafness Or Hearing Loss
 ;;^UTILITY(U,$J,358.3,10370,2)
 ;;=^295322
 ;;^UTILITY(U,$J,358.3,10371,0)
 ;;=V17.3^^67^675^16
 ;;^UTILITY(U,$J,358.3,10371,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10371,1,4,0)
 ;;=4^V17.3
 ;;^UTILITY(U,$J,358.3,10371,1,5,0)
 ;;=5^Family h/o Ischemic Heart Dis
 ;;^UTILITY(U,$J,358.3,10371,2)
 ;;=^295305
 ;;^UTILITY(U,$J,358.3,10372,0)
 ;;=V16.6^^67^675^17
 ;;^UTILITY(U,$J,358.3,10372,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10372,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,10372,1,5,0)
 ;;=5^Family h/o Leukemia
 ;;^UTILITY(U,$J,358.3,10372,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,10373,0)
 ;;=V18.61^^67^675^19
 ;;^UTILITY(U,$J,358.3,10373,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10373,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,10373,1,5,0)
 ;;=5^Family h/o Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,10373,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,10374,0)
 ;;=V17.0^^67^675^20
 ;;^UTILITY(U,$J,358.3,10374,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10374,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,10374,1,5,0)
 ;;=5^Family h/o Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,10374,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,10375,0)
 ;;=V19.4^^67^675^21
 ;;^UTILITY(U,$J,358.3,10375,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10375,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,10375,1,5,0)
 ;;=5^Family h/o Skin Condition
 ;;^UTILITY(U,$J,358.3,10375,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,10376,0)
 ;;=V17.1^^67^675^22
 ;;^UTILITY(U,$J,358.3,10376,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10376,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,10376,1,5,0)
 ;;=5^Family h/o Stroke (CVA)
 ;;^UTILITY(U,$J,358.3,10376,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,10377,0)
 ;;=V16.8^^67^675^12
 ;;^UTILITY(U,$J,358.3,10377,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10377,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,10377,1,5,0)
 ;;=5^Family h/o Cancer,Other Specified
 ;;^UTILITY(U,$J,358.3,10377,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,10378,0)
 ;;=V11.1^^67^675^24
 ;;^UTILITY(U,$J,358.3,10378,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10378,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,10378,1,5,0)
 ;;=5^Hx of Affective Disorder
 ;;^UTILITY(U,$J,358.3,10378,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,10379,0)
 ;;=V15.89^^67^675^46
 ;;^UTILITY(U,$J,358.3,10379,1,0)
 ;;=^358.31IA^5^2
